Global medical device company Elekta (STO:EKTA B) won Japanese regulatory approval for its Agility radiation therapy system, which promises "faster, more accurate cancer treatments on the horizon."

The Agility system utilizes Elekta’s multi-leaf collimator, a "device made up of numerous, individual tungsten ‘leaves’," which shapes radiation therapy beams to deliver treatment from different angles around the patient, according to a press release.

Agility features 160 tungsten leaves, twice as many as typical MLCs, according to the company. The leaves provide more precise radiation beam targeting that helps protects healthy tissue from exposure.

"Culminating from years of close collaboration with our worldwide clinical partners, we are extremely proud to introduce Agility in Japan," Elekta KK president & managing director Tim Rooney said in prepared remarks. "With Agility, not only will treatment times be faster, but patients also will benefit from this solution’s enhanced targeting capabilities, which are expected to improve treatment outcomes and reduce the risk of complications."

Elekta touted FDA approval for the Agility system last month, and earlier this year won CE Mark approval in the European Union.